المؤلفون: Ritsuya Shiiba, Masahiro Sano, Yoshihito Kogure, Hiroto Murao, Yuki Takigawa, Atsushi Torii, Arisa Yamada, Yuka Shinohara, Hideyuki Niwa, Chiyoe Kitagawa, Masahide Oki

المصدر: Respiratory Medicine Case Reports, Vol 49, Iss , Pp 102023- (2024)

مصطلحات موضوعية: Panton-Valentine leukocidin (PVL), Methicillin-resistant Staphylococcus aureus (MRSA), Necrotizing pneumonia, Vancomycin, Linezolid, Diseases of the respiratory system, RC705-779

الوصف: A 22-year-old Vietnamese man was referred to our hospital owing to cough, dyspnea, and difficulty moving. The patient was diagnosed with community-acquired Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and necrotizing pneumonia. Treatment involved vancomycin (VCM) and meropenem, and the MRSA bacteremia improved. However, lung tissue destruction progressed. Therefore, linezolid was added to the VCM regimen, and this intervention led to the patient's recovery, and he was discharged from the hospital. Here, we report a case in which the patient was treated with a combination of two anti-MRSA drugs and was cured.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2213007124000467Test; https://doaj.org/toc/2213-0071Test

الوصول الحر: https://doaj.org/article/8536bacecf094213ad88c7897c378c8dTest

المؤلفون: Hiroto Watanabe, Masahide Oki, Yoshihito Kogure, 小暮 啓人, 沖 昌英, 渡辺 寛仁

المصدر: 肺癌 / Haigan. 2023, 63(6):864

المؤلفون: Daichi Fujimoto, Satoru Miura, Keisuke Tomii, Hiromitsu Sumikawa, Kenichi Yoshimura, Kazushige Wakuda, Yuko Oya, Toshihide Yokoyama, Takashi Kijima, Tetsuhiko Asao, Motohiro Tamiya, Atsushi Nakamura, Hiroshige Yoshioka, Takaaki Tokito, Shuji Murakami, Akihiro Tamiya, Hiroshi Yokouchi, Satoshi Watanabe, Ou Yamaguchi, Ryotaro Morinaga, Takayuki Jodai, Kentaro Ito, Yoshimasa Shiraishi, Yoshihito Kogure, Ryota Shibaki, Nobuyuki Yamamoto

المصدر: Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with pneumonitis. A multicenter, retrospective cohort study of patients with non-squamous non-small cell lung cancer who received a combination of platinum, pemetrexed, and pembrolizumab was conducted. Patients with confirmed pneumonitis established by an independent multidisciplinary team were enrolled. For 53 patients with pneumonitis, radiographic features at diagnosis predominantly comprised an organizing pneumonia pattern (62%, 33/53). Twelve (23%) patients experienced a worsening respiratory status during pneumonitis management, which was associated with a high mortality rate (58%, 7/12) during treatment. Severe grade at pneumonitis diagnosis (p

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/d7954e13f28249d198db8ce843bb07a9Test

المؤلفون: Tomoya Fukui, Jiichiro Sasaki, Satoshi Igawa, Akiko Kada, Toshiki I. Saito, Yoshihito Kogure, Hiroaki Okamoto, Katsuhiko Naoki

المصدر: BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)

مصطلحات موضوعية: Osimertinib, Epidermal growth factor receptor, Non-small cell lung cancer, Poor performance status, First-line chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Cancer chemotherapy indications for patients with poor performance status and advanced lung cancer are limited. Molecular targeted drugs, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, can be used in patients with poor performance status owing to their high efficacy and safety. The third-generation EGFR-tyrosine kinase inhibitor osimertinib has demonstrated effectiveness in the initial treatment of advanced EGFR mutation-positive non-small cell lung cancer in patients with good performance status; however, no evidence exists of the drug’s effectiveness in patients with poor performance status in a prospective study. We designed a study that aims to investigate the efficacy and safety of first-line osimertinib treatment in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations and with poor performance status. Methods The OPEN/TORG2040 study is a multicenter, single-arm, phase II trial for patients with unresectable, advanced EGFR mutation-positive non-small cell lung cancer with a poor performance status (≥ 2). Eligible patients will receive osimertinib until disease progression or unacceptable toxicity. The primary endpoint is the objective response rate of the first-line osimertinib treatment. Considering a threshold value of 45%, expected value of 70% for objective response rate, one-sided significance level of 5%, statistical power of 80%, and ineligible patients, the sample size was set to 30. The secondary endpoints are disease control rate, performance status improvement rate, and safety and patient-reported outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core Quality of Life Questionnaire and Lung Cancer 13. Time to treatment failure, progression-free survival, and overall survival will also be assessed. Discussion Our study can determine the clinical benefits of osimertinib treatment in patients with poor performance status, since the clinical outcomes of patients with EGFR mutation-positive non-small cell lung cancer with poor performance status treated with this drug as a first-line treatment have not been sufficiently evaluated. Trial registration Japan Registry of Clinical Trials: jRCTs041200100 (registration date: February 12, 2021).

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/b7905b38973a4120b686981c1e1fb89fTest

المؤلفون: Yoshihito Kogure, MD, PhD, Akiko Kada, MPH, Hiroya Hashimoto, PhD, Shinji Atagi, MD, Yuichi Takiguchi, MD, Hideo Saka, MD, Noriyuki Ebi, MD, Akira Inoue, MD, Takayasu Kurata, MD, Yuka Fujita, MD, Yoichi Nishii, MD, Hidetoshi Itani, MD, Takeo Endo, MD, Akiko M. Saito, MD, Takuo Shibayama, MD, Nobuyuki Yamamoto, MD, Akihiko Gemma, MD

المصدر: JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100514- (2023)

مصطلحات موضوعية: Squamous-cell non–small cell lung cancer, Elderly, Immune checkpoint inhibitors, Nab-paclitaxel, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Introduction: In the CAPITAL study, a randomized phase 3 study, wherein carboplatin plus nab-paclitaxel treatment was compared with docetaxel treatment for older patients with squamous-cell lung cancer, the former became the new standard of care for such patients. Our study aimed to evaluate whether the efficacy of second-line immune checkpoint inhibitors (ICIs) affected the primary analysis of overall survival (OS). Methods: Herein, we performed a post hoc analysis of the impact of second-line ICIs on OS, safety in each group of participants aged more than 75 years, and intracycle nab-paclitaxel skip status. Results: Patients were randomly allocated to the carboplatin plus nab-paclitaxel (nab-PC) arm (n = 95) or the docetaxel (D) arm (n = 95). Of these patients, 74 of 190 (38.9%) were transferred to ICIs for second-line treatment (nab-PC arm: 36, D arm: 38). A survival benefit was numerically observed only for patients for whom first-line therapy was terminated owing to disease progression (median OS [nab-PC arm]: with and without ICIs, 321 and 142 d, respectively; median OS [D arm]: with and without ICIs, 311 and 256 d, respectively). The OS among patients who received ICI after adverse events was similar in the two arms. In the D arm, a significantly higher frequency of grade greater than or equal to 3 adverse events was observed among patients aged more than or equal to 75 years (86.2%) than among those aged less than 75 years (65.6%, p = 0.041), including a significantly higher frequency of neutropenia (84.6% versus 62.5%, p = 0.032); no such differences were observed in the nab-PC arm. Conclusions: We found that second-line ICI treatment seemed to have a little impact on OS.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S266636432300053XTest; https://doaj.org/toc/2666-3643Test

الوصول الحر: https://doaj.org/article/4876c2feeaf34060b78e84539b872f0eTest

المؤلفون: Masahide Oki, Hideo Saka, Yoshihito Kogure, Hideyuki Niwa, Akane Ishida, Arisa Yamada, Atsushi Torii, Chiyoe Kitagawa

المصدر: BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-8 (2022)

مصطلحات موضوعية: Bleeding, Bronchoscopy, Complications, Cryobiopsy, Thin bronchoscope, Diseases of the respiratory system, RC705-779

الوصف: Abstract Background Transbronchial lung cryobiopsy is useful when diagnosing lung lesions. However, prevention of associated bleeding complications is essential. This study aimed to evaluate the safety and efficacy of our novel bronchoscopic cryobiopsy technique, which uses a long nasobronchial tube to prevent blood flooding the central airway. Methods Patients with localized or diffuse lung lesions were prospectively enrolled and underwent cryobiopsy using a 1.9 mm diameter cryoprobe and a 4.0 mm diameter thin bronchoscope under conscious sedation. For cryobiopsy, a long silicone tube (inner diameter, 5.0 mm) was advanced through the nose to the target bronchus, then wedged to drain blood under thin-tube bronchoscopic control. The primary endpoint was the frequency of bleeding complications. Results Of the 80 patients initially enrolled, 73 that underwent at least one cryobiopsy were ultimately included. Mild bleeding during cryobiopsy occurred in 58 patients (79.5%), but there was no moderate or severe bleeding. Other complications occurred in four patients (two pneumothorax, one pneumomediastinum, and one pneumonia). Tube dislocation was noted in eight patients (11%). Cryobiopsy specimens were significantly larger than forceps biopsy specimens (9.0 mm2 vs. 2.7 mm2, P

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2466Test

الوصول الحر: https://doaj.org/article/989544f9f5b744a2a90a776624b07480Test

المؤلفون: Hideyuki Niwa, Masahide Oki, Yurika Ishii, Atsushi Torii, Arisa Yamada, Yuka Shinohara, Yoshihito Kogure, Hideo Saka

المصدر: Thoracic Cancer, Vol 13, Iss 12, Pp 1783-1787 (2022)

مصطلحات موضوعية: endobronchial ultrasonography, geriatric oncology, non‐small cell lung cancer, bronchoscopy, small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background The safety and efficacy of endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) in patients aged 70 years and older has been established. However, few studies have evaluated the safety, usefulness, and significance of EBUS‐TBNA in patients aged 80 years and older. Methods We retrospectively investigated patients aged 80 years and older who underwent EBUS‐TBNA under local anesthesia. The study period was 10 years; from November 1, 2010 to October 31, 2020. The primary endpoint was the safety of EBUS‐TBNA, which was measured as the incidence of complications associated with the procedure. The secondary endpoints were the overall diagnostic rate, malignant disease diagnosis rate, and malignant disease treatment rate. Results A total of 111 patients were enrolled in the study, and the median age was 82 years (range: 80–89 years). The incidence of complications (the primary endpoint) was 5% (5/111) and comprised oversedation in one case, chest pain in one case, hypoxemia in two cases, and arrhythmia in one case. Regarding the secondary endpoints, the diagnostic rate for all patients was 75% (83/111), and the diagnostic rate of malignant disease was 89% (75/84). Of the 75 patients with malignant disease diagnosed with EBUS‐TBNA, 61 (81%) received tumor‐specific therapy in accordance with their diagnoses. Conclusion EBUS‐TBNA can be considered safe and effective even in patients aged 80 years and older.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1759-7706Test; https://doaj.org/toc/1759-7714Test

الوصول الحر: https://doaj.org/article/fb208000e71e4858b516a328a5273131Test

المؤلفون: Taichi Miyawaki, Hirotsugu Kenmotsu, Hideyuki Harada, Yasuhisa Ohde, Yasutaka Chiba, Koji Haratani, Tamio Okimoto, Tomohiro Sakamoto, Kazushige Wakuda, Kentaro Ito, Takehiro Uemura, Shinya Sakata, Yoshihito Kogure, Yasumasa Nishimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto

المصدر: BMC Cancer, Vol 21, Iss 1, Pp 1-6 (2021)

مصطلحات موضوعية: Clinical trial, Programmed cell death 1 inhibitor, Oligometastatic disease, Local ablative therapy, Progression-free survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the limited number of metastases at the time of diagnosis. Several clinical trials have shown that local ablative therapy (LAT) at all sites of the disease might be beneficial for patients with oligometastatic NSCLC. In recent years, the combination of programmed cell death 1 (PD-1) inhibitors or programmed cell death ligand 1 with cytotoxic chemotherapy has become a new standard treatment for patients with metastatic NSCLC. Furthermore, multisite LAT would inherently reduce the overall tumour burden, and this could promote T cell reinvigoration to enhance the efficacy of PD-1 inhibitors. Few studies have evaluated the efficacy of the combination of PD-1 inhibitors with LAT at all sites of disease. The aim of the present multicentre single-arm phase II study is to evaluate the efficacy of LAT at all sites of disease following standard platinum doublet chemotherapy with pembrolizumab in patients with oligometastatic NSCLC. Methods Thirty patients with synchronous oligometastatic NSCLC will be enrolled in the trial. All patients will receive 2–4 cycles of a systemic treatment including pembrolizumab and chemotherapy as induction therapy. Patients who will receive LAT will be determined by a multidisciplinary tumour board, including medical oncologists, radiation oncologists, and thoracic surgeons. LAT will be administered at all sites of disease within 21–56 days of the last dose of induction therapy and will be followed by maintenance therapy within 42 days of the last day of LAT. The primary endpoint is the progression-free survival (PFS) rate of 24 months from the date of initiation of LAT. The secondary endpoints are toxicity, response to induction therapy, PFS, overall survival, and the frequency of LAT. Discussion This study will provide novel data on the efficacy and safety profile of the combination of LAT and chemotherapy plus immune-checkpoint inhibitors in patients with synchronous oligometastatic NSCLC. If the primary endpoint of this study is met, extensive phase III studies further assessing this strategy will be recommended. Trial registration jRCT identifier: jRCTs041200046 (date of initial registration: 28 October 2020).

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/39dfc6480ce2459281803dd7cfc8bd88Test

المؤلفون: Arisa Yamada, Atsushi Torii, Chiyoe Kitagawa, Hideo Saka, Hideyuki Niwa, Masahide Oki, Toshihiro Ohama, Yoshihito Kogure, Yuka Shinohara, Yurika Ishii, 丹羽 英之, 北川 智余恵, 坂 英雄, 大濱 敏弘, 小暮 啓人, 山田 有里紗, 沖 昌英, 石井 友里加, 篠原 由佳, 鳥居 厚志

المصدر: 気管支学 / The Journal of the Japan Society for Respiratory Endoscopy. 2021, 43(6):667

المؤلفون: Akane Ishida, Arisa Yamada, Atsushi Torii, Chiyoe Kitagawa, Fumie Shigematsu, Hideo Saka, Hideyuki Niwa, Masahide Oki, Yoshihito Kogure, Yurika Ishii

المصدر: The Tohoku Journal of Experimental Medicine. 2021, 255(2):105